Gilead Sciences, Inc. GILD
167.67 USD -0.41 (-0.24%)
As ofNov 16, 2026, 3:27 PM EST
166.92 Day range 171.80
118.30 52-week range 174.48
- YTD
- +36.61%
- 1 year
- +34.11%
News
benzinga.com Barclays Maintains Equal-Weight on Gilead Sciences, Raises Price Target to $160 Barclays analyst Emily Field maintains Gilead Sciences (NASDAQ:GILD) with a Equal-Weight and raises the price target from $145 to $160.
247wallst.com How Retirees Can Turn $50,000 Into Passive Income With These 4 Dividend Stocks Selling shares in a down market can lock in losses just when retirees need cash most. Four dividend payers from telecom, asset management, biopharma and pizza offer another route, though one of them…
defenseworld.net 31,340 Gilead Sciences, Inc. $GILD Shares Bought by Aberdeen Group plc Aberdeen Group plc raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 3.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities…
zacks.com Can Gilead Sciences' HIV Business Fuel Sustainable Long-Term Growth? GILD's HIV franchise gains momentum as Yeztugo sales surge, Biktarvy maintains market leadership and an expanding pipeline strengthens long-term growth prospects.
marketbeat.com 3 Pharmaceutical Stocks That Offer Safety and Growth Market volatility is unpleasant, but it's important that investors don't force themselves into a false choice between safety and growth. Over the last two years, technology stocks, particularly AI…
defenseworld.net Gilead Sciences, Inc. $GILD Stock Sold by Allspring Global Investments Holdings LLC Allspring Global Investments Holdings LLC reduced its position in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 33.6% in the third quarter, according to its most recent filing with the SEC. The…
benzinga.com EXCLUSIVE: Lilly, Gilead Face Near-Term Drug Pricing Risks As Washington Turns Up Heat The next wave of U.S. drug-price negotiations could put billions of dollars in pharmaceutical revenue under pressure, with Eli Lilly and Co (NYSE:LLY), Gilead Sciences, Inc. (NASDAQ:GILD) facing more…
benzinga.com EXCLUSIVE: Lilly, Gilead Face Near-Term Drug Pricing Risks As Washington Turns Up Heat Democrats have two ways to pressure drugmakers. Eli Lilly, Gilead, Merck, Bristol Myers face different levels of Medicare pricing exposure.
seekingalpha.com Gilead Sciences, Inc. (GILD) Presents at 8th Annual Wolfe Research Healthcare Conference Transcript Gilead Sciences, Inc. (GILD) Presents at 8th Annual Wolfe Research Healthcare Conference Transcript
marketbeat.com Gilead Sciences Targets 200 Treatment Centers for Potential Anito-Cel Launch Gilead Sciences NASDAQ: GILD is preparing for a potential launch of its multiple myeloma cell therapy anito-cel, with plans to build on the treatment-center relationships and manufacturing…
fool.com Gilead Sciences Stock Hits a New All-Time High: Is it Still a Good Buy? The healthcare company's growth rate has been showing significant improvement in recent periods. Its diversified business has been generating positive growth across multiple therapeutic areas.
benzinga.com Hims-Eli Lilly GLP-1 Deal Meets Summit’s FDA Gamble: Which Biotech ETFs Stand to Gain? Biotech ETFs face key FDA catalysts as Summit Therapeutics' decision and the Hims-Lilly GLP-1 deal put XLV, IBB and XBI in focus.
benzinga.com Gilead Highlights Strong Trial Results in HIV Prevention and Liver Disease Gilead reports high persistence for twice-yearly HIV shot lenacapavir and strong Phase 3 Livdelzi response in primary biliary cholangitis.
benzinga.com Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 3.47% on an annualized basis producing an average annual return of 12.13%. Currently, Gilead Sciences has a market…benzinga.com Gilead’s Twice-Yearly HIV Prevention Injection Shows 85.6% Persistence And Zero HIV Acquisitions in 52-Week Trial Gilead Sciences, Inc. (NASDAQ:GILD) today announced results from the PURPOSE 5 trial showing significantly higher persistence—defined as consistent and continuous on-time use—among people starting…
benzinga.com Gilead Sciences Reports Phase 3 IDEAL Success For Livdelzi In PBC, With 75.4% Achieving ALP Normalization At Week 52 Vs 16.1% Placebo; Serious Adverse Events 3.1% Livdelzi Vs 12.9% Placebo; None Related To Drug - Data to be Presented at The Liver Meeting® Demonstrate Rapid and Sustained Improvements in ALP Levels with Livdelzi in Adults with PBC and ALP Levels Between 1-1.67× ULN, Despite Receiving UDCA or…
benzinga.com Gilead Sciences To Present 23 Presentations At 68th American Society of Hematology Annual Meeting Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, today announced 23 presentations, including 7 oral presentations, will be presented at the 68th American Society of Hematology (ASH)…
benzinga.com Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 3.29% on an annualized basis producing an average annual return of 12.2%. Currently, Gilead Sciences has a market…benzinga.com JP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $190 JP Morgan analyst Chris Schott maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $170 to $190.
benzinga.com TD Cowen Maintains Buy on Gilead Sciences, Raises Price Target to $175 TD Cowen analyst Tyler Van Buren maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $160 to $175.
benzinga.com Morgan Stanley Maintains Overweight on Gilead Sciences, Raises Price Target to $183 Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $163 to $183.
benzinga.com Wells Fargo Maintains Overweight on Gilead Sciences, Raises Price Target to $190 Wells Fargo analyst Mohit Bansal maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $165 to $190.
benzinga.com Truist Securities Maintains Buy on Gilead Sciences, Raises Price Target to $181 Truist Securities analyst Gregory Renza maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $158 to $181.
benzinga.com RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $131 RBC Capital analyst Brian Abrahams maintains Gilead Sciences (NASDAQ:GILD) with a Sector Perform and raises the price target from $126 to $131.
benzinga.com Gilead CEO Takes Aim at Medicare Pricing: 'Pill Penalty' Threatens Drug Innovation Gilead stock rose after Q3 earnings beat Wall Street estimates and strong HIV drug demand prompted an increased 2026 sales forecast.
benzinga.com Incyte To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Friday Analysts raised targets for Cheniere and Incyte, while cutting Stryker, Roblox, Intel and Honeywell; Bright Horizons was downgraded.
benzinga.com These Analysts Increase Their Forecasts On Gilead Sciences After Upbeat Q3 Results Gilead beats Q3 estimates, raises 2026 sales guidance but cuts EPS outlook; shares rise 4.1% as analysts lift price targets.benzinga.com Cantor Fitzgerald Maintains Overweight on Gilead Sciences, Raises Price Target to $175 Cantor Fitzgerald analyst Carter Gould maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $155 to $175.
benzinga.com Needham Maintains Buy on Gilead Sciences, Raises Price Target to $200 Needham analyst Joseph Stringer maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $170 to $200.
benzinga.com Gilead Sciences Q3 2026 Earnings Call Transcript Gilead Sciences (NASDAQ:GILD) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…benzinga.com Gilead Sciences Lowers FY2026 GAAP EPS Guidance from $(3.75)-$(3.40) to $(4.40)-$(4.05) vs $(3.44) Est Gilead Sciences (NASDAQ:GILD) lowers FY2026 GAAP EPS guidance from $(3.75)-$(3.40) to $(4.40)-$(4.05) vs $(3.44) analyst estimate..
benzinga.com Gilead Sciences Lowers FY2026 Adj EPS Guidance from $(0.65)-$(0.30) to $(1.20)-$(0.85) vs $(0.47) Est; Raises FY2026 Sales Guidance from $30.100B-$30.400B to $31.000B-$31.300B vs $30.767B Est Gilead Sciences (NASDAQ:GILD) lowers FY2026 Adj EPS guidance from $(0.65)-$(0.30) to $(1.20)-$(0.85) vs $(0.47) analyst estimate. Raises FY2026 sales outlook from $30.100 billion-$30.400 billion to…
benzinga.com Gilead Sciences Q3 Adj. EPS $2.55 Beats $2.19 Estimate, Sales $8.300B Beat $7.809B Estimate Gilead Sciences (NASDAQ:GILD) reported quarterly earnings of $2.55 per share which beat the analyst consensus estimate of $2.19 by 16.44 percent. This is a 3.24 percent increase over earnings of…
benzinga.com Alphabet Sinks 11.8%, Small Caps Rally on Strong GDP Growth: Stock Market Today Alphabet's capex-heavy quarter drags the Nasdaq 100 lower while GDP beats and the Russell 2000 rallies, with three of four large caps rising.
benzinga.com Amazon, Eli Lilly On Deck Thursday As AWS Growth, Drug Demand Face Test Amazon headlines Thursday’s reports, with investors focused on whether accelerating AWS growth and heavy AI spending can support the next leg of its expansion. Eli Lilly, Mastercard, Merck,…
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…benzinga.com Gilead Sciences Agrees To Acquire Oral IL-23R Inhibitor Program From PepStar Therapeutics Under $1.275B Deal Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire an oral IL-23R inhibitor program, including lead asset HCXT-2001, from PepStar…
benzinga.com BioNTech Enters Clinical Trial Collaboration And Supply Agreement With Gilead Sciences To Evaluate Pumitamig In Combination With Sacituzumab Govitecan As First-Line Treatment For Patients With Locally Advanced Or Metastatic PD-L1 Low Or Negative Triple-negative Breast Cancer Pumitamig is an investigational bispecific immunomodulator designed to cooperatively bind to PD-L1 and VEGF-A that is being jointly developed by BioNTech and Bristol Myers Squibb ("BMS").ROSETTA…
benzinga.com Occidental Petroleum To Rally Over 18%? Here Are 10 Top Analyst Forecasts For Tuesday Analysts cut targets for WING, ELAN, SBAC and RH; raised targets for TRV, OXY and GILD, with ELAN downgraded to Hold.benzinga.com B of A Securities Maintains Buy on Gilead Sciences, Raises Price Target to $172 B of A Securities analyst Tim Anderson maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $168 to $172.
benzinga.com Gilead Bolsters Inflammatory Bowel Disease Pipeline With Promising Mid-Stage Trial Success Gilead Sciences announced positive Phase 2 SWIFT trial results for emvistegrast, an oral treatment for active ulcerative colitis.mexc.com Co-Diagnostics, Inc. ( CODX ) Previous Close The stock's closing price from the previous trading day, used as a reference for today's price change. P/E Ratio The price-to-earnings ratio, calculated by dividing the share price by…
247wallst.com Strategy spends $245 million on Bitcoin funded by a fresh share sale Strategy, the software-turned-Bitcoin-treasury company led by Michael Saylor, acquired roughly $245 million worth of Bitcoin ...
247wallst.com DeItaone on X: “$MSTR - STRATEGY RAISES $244.7M FROM SHARE SALE, BUYS MORE BITCOIN Strategy disclosed new…” Nov 14, 6:00am ET Jensen Huang is Out at Nvidia & Bitcoin is Crashing?! \| Jordi Visser. Visser: analysts slashed Nvidia ...
247wallst.com iQIYI (IQ) Drops 12.4% on Q3 2026 Earnings Filing Day For a stock already trading at these price levels, a single-session decline of 12.4% marks a sharp erosion of value, and lower-priced shares are more sensitive to earnings-driven ...
ainvest.com Vir Biotechnology's Hepatitis Delta Win Came With a $150 Million Bill Vir Biotechnology announced successful Phase 3 trial results for its hepatitis delta drug combination, followed by a $150M ...
finance.yahoo.com Which Healthcare ETF Is Best for the Long Term: State Street’s XPH or Invesco’s PBE? Lower fees and a steadier beta set one healthcare ETF apart, while the rival fund's richer dividend could sway income-focused ...
finance.yahoo.com How Retirees Can Turn $50,000 Into Passive Income With These 4 Dividend Stocks Selling shares in a down market can lock in losses just when retirees need cash most. Four dividend payers from telecom, ...
finance.yahoo.com Better Healthcare ETF: Invesco's PJP vs. Simplify's PINK Concentrated pharma exposure delivered 31% returns over one year, while active healthcare management achieved 18%.
fidelity.co.uk Gilead Sciences Inc (GILD) Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of…
